BIOCON

arm gets approval for jobevne a cancer medicine

's subsidiary Biocon Biologics has received U.S. FDA approval for Jobevne, a biosimilar to Bevacizumab, enhancing its oncology portfolio. This approval aims to improve access to affordable cancer treatments in the United States. Stock Performance 's stock closed at Rs 305.20, down 5.33% from the previous day’s close of Rs 322.40. The stock has seen fluctuations, hitting an intraday low of Rs 303.85. Year-to-date, Biocon shares have gained 12.43% but have also experienced a decline of 17.25%. Market Metrics The total trading volume was 1.63 lakh shares, resulting in a turnover of Rs 5.03 crore. The market capitalization of Biocon is now Rs 36,642 crore. The stock's 52-week high was Rs 404.60 on January 21, 2025, while the low was Rs 260 on April 19, 2024. Jobevne Overview Jobevne (bevacizumab-nwgd) is a recombinant humanized monoclonal antibody used for treating various cancers. It functions as a vascular endothelial growth factor (VEGF) inhibitor, blocking the interaction with its receptors to prevent angiogenesis, thereby limiting blood supply to tumors. This approval marks Biocon Biologics' seventh biosimilar approved in the U.S., adding to its oncology offerings, which include OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). CEO Statement Shreehas Tambe, CEO & Managing Director of Biocon Biologics, emphasized the significance of this approval as a testament to the company's scientific expertise and commitment to providing high-quality, affordable biologics. In 2023, U.S. sales of bevacizumab were approximately $2.0 billion, indicating a substantial market opportunity for Jobevne. Disclaimer- Investment in the share market is subject to market risk, and past performance is not indicative of future results. Recommendations are for informational purposes only and should not be considered as buy or sell advice. Please conduct your own research and consult a financial advisor before making any investment decisions.